Scandinavian deal to co-develop new type of antithrombotic therapy

Finland’s Aplagon and Cadila Pharmaceuticals Sweden have agreed a co-development and commercialization deal to develop a new kind of antithrombotic product discovered by the Finnish firm.

India-based Cadila and its Swedish subsidiary will undertake formulation development with a Phase I trials in a selected first indication to prevent vascular intervention-related blood vessel occlusions.

Following additional pre-clinical studies required in India, it is anticipated that the first Indian clinical trial will start recruiting in 2019.

Cadila will pay for much of the development and will receive the commercialization rights for India and a share of future commercialization proceeds outside India.

Aplagon will receive a royalty on Indian sales and will retain commercialization rights for products in other jurisdictions outside India. Financial terms were not disclosed.